Overview

Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers

Status:
Not yet recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical study of MSP008-22, the Investigational Medicinal Product (IMP). The current study is designed to evaluate the safety and tolerability and pharmacokinetics of single and multiple oral doses of the IMP (MSP008-22) in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Godavari Biorefineries Limited